Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We explored and validated the association of postoperative carcinoembryonic antigen (CEA) with disease-free survival (DFS) and overall survival (OS) in stage III colon cancer.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Epidemiol Biomarkers Prev

Title: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Publisher: American Association for Cancer Research (AACR)

ISSN (Electronic): 1538-7755

ISSN (Print): 1055-9965

Publication date (Electronic): July 2019

Volume: 28

Issue: 7

Affiliations

[1 ] Sorbonne Paris-Cité, Paris Descartes University, Hepato-Gastroenterology and Gastrointestinal Oncology Department, Hôpital Européen Georges Pompidou, Paris, France.

[2 ] Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France.

[3 ] University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.

[4 ] Department of Gastroenterology, CHU Le Bocage, INSERM U1231, Dijon, France.

[5 ] Department of Gastroenterology and Digestive Oncology, Hôpital Saint Louis, Sorbonne Paris-Cité, Paris Diderot University, Paris, France.

[6 ] Department of Gastroenterology, Centre Hospitalier Départemental Les Oudairies, La Roche-Sur-Yon, France.

[7 ] Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

[8 ] Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany.

[9 ] Institut Catala d'Oncologia, Oncobell Program, IDIBELL, CIBERONC, University of Barcelona. L'Hospitalet de Llobregat, Barcelona, Spain.

[10 ] Oncology Multidisciplinary Research Group (GERCOR), Paris, France.

[11 ] Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy.

[12 ] Unit of Medical Oncology, Institut Mutualiste Montsouris, Paris, France.

[13 ] Gastroenterology and Digestive Department, Hopital Erasme, Université Libre de Bruxelles, Belgium.

[14 ] Vall d'Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC, University of Barcelona, Barcelona, Spain.

[15 ] Department of Oncology, Royal Bournemouth Hospital and Bournemouth University, Bournemouth, England.

[16 ] Department of Oncology, Institut Hospitalier Franco-Britannique, Levallois-Perret, France.

[17 ] Sorbonne University and Department of Medical Oncology, Hospital Saint Antoine, Paris, France.

[18 ] Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France. dvernerey@chu-besancon.fr.

Article

Publisher Item ID: 1055-9965.EPI-18-0867

DOI: 10.1158/1055-9965.EPI-18-0867

PubMed ID: 31263053

SO-VID: 877c58ec-0012-4823-9b5d-a13f13a70a8b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 8

See all cited by